Novo Nordisk Faces 5 Key Questions, Says Analyst
Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...
Novo Nordisk Expands Drug Discovery Collaboration With Valo Health For Cardiometabolic Diseases
Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...
Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact — Update
Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence. The deal extends ...
Variant Bio and Novo Nordisk to identify targets for metabolic disease treatment
Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.